EXACT SCIENCES CORP (EXAS) Research & Development (2010 - 2025)

Exact Sciences (EXAS) has reported Research & Development for 16 consecutive years, with $288.5 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Research & Development rose 17.99% year-over-year to $288.5 million in Q4 2025; TTM through Dec 2025 was $1.1 billion, a 17.45% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 17.45% from the prior year.
• Research & Development was $288.5 million for Q4 2025 at Exact Sciences, up from $250.2 million in the prior quarter.
• Over five years, Research & Development peaked at $293.8 million in Q4 2022 and troughed at $186.1 million in Q1 2021.
• A 5-year average of $228.2 million and a median of $217.2 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 70.42% in 2021 and declined 26.29% in 2023, its largest moves.
• Over 5 years, Research & Development stood at $284.3 million in 2021, then rose by 3.36% to $293.8 million in 2022, then declined by 26.29% to $216.6 million in 2023, then grew by 12.9% to $244.5 million in 2024, then gained by 17.99% to $288.5 million in 2025.
• The last three Research & Development figures came in at $288.5 million (Q4 2025), $250.2 million (Q3 2025), and $247.1 million (Q2 2025), per Business Quant data.